AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03197675 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Participants within the acupuncture treatment group will receive traditional body acupuncture with electrical stimulation for 30 minutes three times a week, additionally participants will also receive auricular acupuncture once a week with the needles retained in both ears for seven days and replaced the following week, for a total of eight weeks (24 treatments of conventional acupuncture and 8 treatments of auricular acupuncture). Relative pain levels will be measured via the NRS by a member of the research staff before and after each treatment. All participants will then be reevaluated with the described assessment tools at three months and again at six months. Acupuncturists will not participate in the three and six month evaluations of subjects.
Study NCT03887637 — intervention group
Intervention type: DRUG
Intervention: DAAs
Description: Patients with CHC and cirrhosis who fulfills the indication of antiviral therapy will be administered with DAAs treatment.
Study NCT03084900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 1
Description: Patient-Centered Decision Support to Improve Diabetes Mgmt. We will use a computerized decision support system to aid clinicians to provide standard of care management while introducing patient-centered guidelines and outcomes measures.The intervention is the use of an electronic decision support tool. The decision support tool consists of a series of questions answered by the patients that will then allow the health care provider to address specific needs during the visit.
Study NCT03793179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Given IV
Study NCT03793179 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT03793179 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT04698889 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: natural cow
Study NCT04698889 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: high protein cow milk
Study NCT04698889 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: natural human
Study NCT04698889 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low protein cow milk
Study NCT02518139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208
Description: Subjects receiving TD-4208 are blinded to one of two doses of 4208.
Study NCT01994720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: ticagrelor, 180 mg (two tablets of 90 mg) loading dose on Day 1 followed by 90 mg twice daily.
Study NCT01994720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Description: ASA, 300 mg (three tablets of 100 mg) on Day 1, followed by 100 mg once daily.
Study NCT00146640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR Prednisone
Description: Participants will receive tablets containing MR prednisone (to achieve the appropriate dose of 3-10 milligrams \[mg\] prednisone per day) at bed time.
Study NCT00146640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IR Prednisone
Description: Participants will receive tablets containing IR prednisone (to achieve the appropriate dose of 3-10 mg prednisone per day) in the morning.
Study NCT00146640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - MR Prednisone
Description: Participants will receive placebo matching to MR prednisone tablet at bed time.
Study NCT00146640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - IR Prednisone
Description: Participants will receive placebo matching to IR prednisone tablet in the morning.
Study NCT01988519 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed gravity drain
Description: passive tube drains (PFM Medical, Köln, Germany)
Study NCT01988519 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closed suction drain
Description: BLAKE Silicon drains (Ethicon, USA)
Study NCT03073629 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Pathway
Description: Patients will be evaluated and managed in a specialized cardiovascular clinic to determine the etiology of right heart failure and begin treatment.
Study NCT03805464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee Joint Effusion
Description: 60mL saline injection into the supra-patellar region of the knee
Study NCT01364961 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol capsules
Description: 2 x 75 mg resveratrol each day, for 4 weeks
Study NCT01364961 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol capsules
Description: 2 x 75 mg resveratrol each day, for 4 weeks
Study NCT02821390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac Eye Drops
Description: One drop instilled to the eye's cul de sac prior to the intravitreal injection.
Study NCT02821390 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Artificial Tears)
Description: One drop instilled to the eye's cul de sac prior to the intravitreal injection
Study NCT04166695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monolithic / facially veneered zirconia fixed partial denture
Description: Participant receives one monolithic / facially veneered zirconia fixed partial denture retained by either teeth, implants or teeth and implants for the replacement of two neighbouring posterior teeth.
Study NCT01690234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention
Description: Early coordinated multidisciplinary intervention. Physiotherapist, chiropractor, rheumatologist, psychologist, occupational physician, ergonomist and social worker/case manager.
Study NCT01690234 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Intervention from physiotherapist, chiropractor, rheumatologist and social worker.
Study NCT04166695 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Completely veneered CoCr fixed partial denture
Description: Participant receives one completely veneered CoCr fixed partial denture retained by either teeth, implants or teeth and implants for the replacement of two neighbouring posterior teeth.
Study NCT04545619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QDOT MICRO System
Description: QDOT Micro Catheter with nGEN Generator
Study NCT02013687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25 VLP- FhCMB
Study NCT03291197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suprascapular and median nerve blocks
Description: Ultrasound guided injection of the median and suprascapular nerve of the affected side.
Study NCT02723162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline (VRN)
Description: VRN will be provided at the standard recommended dose (0.5 mg daily for 3 days, then 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for the remaining 21 days of active treatment.
Study NCT02723162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline (VRN)
Description: VRN will be provided at the standard recommended dose (0.5 mg daily for 3 days, then 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for the remaining 21 days of active treatment.
Study NCT02046538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m2 IV over two hours (or administered concurrently with oxaliplatin or irinotecan, depending on the assigned regimen)
Study NCT02046538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 400 mg/m2 IV over two hours (or administered concurrently with oxaliplatin or irinotecan, depending on the assigned regimen)
Study NCT02046538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 IV over two hours
Study NCT02046538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/m2 IV over two hours
Study NCT02046538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
Study NCT02046538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
Study NCT02046538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 IV over 90 minutes
Study NCT02046538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m2 IV over 90 minutes
Study NCT04779164 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: knee ultrasonography
Description: The knees of all patients were screened with ultrasonography device for the measurement of femoral cartilage thicknesses.
Study NCT02723162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine (NAC)
Description: NAC will be dosed at 1200 mg twice daily throughout the 28-day active treatment
Study NCT02723162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC)
Description: NAC will be dosed at 1200 mg twice daily throughout the 28-day active treatment
Study NCT02723162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT02723162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT02518139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: There is not a placebo, there is an active comparator (Tiotropium) arm.
Study NCT04779164 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: knee ultrasonography
Description: The knees of all patients were screened with ultrasonography device for the measurement of femoral cartilage thicknesses.
Study NCT04305236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO
Study NCT04305236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given Intramuscularly
Study NCT01793246 — intervention group
Intervention type: DEVICE
Intervention: probe based laser endomicroscopy (pCLE)
Description: pCLE will be added to standard bronchoscopy for the purpose of characterizing lung cancer or for characterizing of acute rejection in transplanted lungs.
Study NCT03598231 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sacral neuromodulation
Description: After the definitive implantation, stimulators are placed in position OFF for the first arm and in position ON for the second arm during 4 weeks.~Then all the stimulators are switched OFF (both first and second arms) for 2 weeks.~Finally stimulators are maintained in position ON for the first arm and switched OFF for the second arm during 4 weeks.~Since this is a cross-over study, patients can be randomly assigned to any arm first, but they will go to the other arm since the patient is its own control. 50% of randomized patients will go through ON-OFF and the other 50% OFF-ON.~After this cross-over phase, ALL stimulators will be in ON position until the end of the study period.
Study NCT03598231 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral neuromodulation
Description: After the definitive implantation, stimulators are placed in position OFF for the first arm and in position ON for the second arm during 4 weeks.~Then all the stimulators are switched OFF (both first and second arms) for 2 weeks.~Finally stimulators are maintained in position ON for the first arm and switched OFF for the second arm during 4 weeks.~Since this is a cross-over study, patients can be randomly assigned to any arm first, but they will go to the other arm since the patient is its own control. 50% of randomized patients will go through ON-OFF and the other 50% OFF-ON.~After this cross-over phase, ALL stimulators will be in ON position until the end of the study period.
Study NCT01380496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline monohydrate
Description: tablet, 100 mg, single, oral dose
Study NCT01380496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline monohydrate
Description: Capsule, 100 mg, single, oral dose
Study NCT01539434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural intervention
Description: Patients in the behavioural intervention group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active. The behavioural intervention to support physical activity behaviour includes weekly motivational interviewing telephone calls for the first month, two telephone calls for the following two months and thereafter monthly telephone calls.
Study NCT01539434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care group
Description: Patients in the usual care group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active.
Study NCT04047069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Awareness Training and Person-Centered Occupational Therapy Intervention
Description: Exp. identifying the activities the person wants to do, suggestions to facilitate the activity, arranging the activity according to the needs of the person, arranging the environment so that the environment can be a facilitating factor in the activities the person wants to do.
Study NCT04047069 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Awareness Training
Description: Exp.~* General information about HD~* Approaches to Coping with HD Symptoms~* Self care skills (eg hygiene)
Study NCT03806296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increase morning bright light
Description: Participants will wear Re-Timer bright glasses for 30 minutes each morning
Study NCT03806296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decrease evening blue light
Description: Participants will wear tinted glasses that block blue wavelength light for 2 hours before bed
Study NCT03806296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep scheduling
Description: Participants will advance their weekday bedtime and maintain their weekday risetime on weekends
Study NCT03806296 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitor sleep, mood, and substance use
Description: Participants will monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraphy
Study NCT03806296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitor sleep, mood, and substance use
Description: Participants will monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraphy
Study NCT02469961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Participants will receive an interscalene block and will be sedated with Dexmedetomidine and compared to sedation with propofol
Study NCT02469961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Participants will receive an interscalene block and be sedated with Propofol and compared to sedation with Dexmedetomidine
Study NCT02469961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: Interscalene block is used for the main anesthetic for the case
Study NCT00391638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRUVADA (EMTRICITABINE + TENOFOVIR DF)
Description: Truvada ® (200 mg tablet of 300 mg of emtricitabine + tenofovir DF) Dosage 1 tablet taken orally once a day
Study NCT00391638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGASYS 180μg (Interféron pégylé alpha -2a)
Description: Pegasys ® injection 180μg Dosage: A subcutaneous injection per week
Study NCT03826953 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nurse Led Allergy Clinic
Description: Project to investigate if it is feasible to establish a nurse-led primary care-based allergy clinic intervention in NHS Lothian, and to understand the acceptability and estimate the impact of this service on improving access and outcomes in patients with allergic conditions.WE will undertake a mixed-methods longitudinal evaluation of the community-based nurse-led allergy clinic.
Study NCT01174784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chronic TOtAl OcclusioN CrossiNg with thE WildCat CatheTer
Description: A Non-Randomized Study of the Avinger Wildcat™ used to Cross Chronic Total Occlusions in the Superficial Femoral and Popliteal Arteries
Study NCT03241173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01949
Description: In Phase 1, participants will receive INCAGN01949 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will receive INCAGN01949 administered IV at the recommended dose from Phase 1.
Study NCT03523000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intrathecal infusion of normal saline at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
Study NCT03523000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intrathecal infusion of normal saline at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
Study NCT03523000 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Drug Delivery System (IDDS)
Description: 40-mL IDDS containing a solution of fentanyl 50 mcg/mL with bupivacaine 30 mg/mL
Study NCT03523000 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intrathecal Drug Delivery System (IDDS)
Description: 40-mL IDDS containing a solution of fentanyl 50 mcg/mL with bupivacaine 30 mg/mL
Study NCT00823342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CLEVUDINE + TENOFOVIR PLACEBO
Description: 30 MG
Study NCT00823342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CLEVUDINE IN ASSOCIATION TENOFOVIR
Description: TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd
Study NCT00823342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TENOFOVIR + CLEVUDINE PLACEBO
Description: TENOFOVIR 300 mg qd + CLEVUDINE Placebo
Study NCT02687659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEMIS system
Description: Wearing TEMIS system over the day during one week
Study NCT02503345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLN-177 low dose
Description: ALLN-177 1,500 units (1 capsule)/meal PO 3 times per day
Study NCT02503345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLN-177 mid dose
Description: ALLN-177 3,000 units (2 capsules)/meal PO 3 times per day
Study NCT02503345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLN-177 high dose
Description: ALLN-177 7,500 units (5 capsules)/meal PO 3 times per day
Study NCT02503345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 1, 2 or 5 capsules with meals PO 3 times per day
Study NCT03826576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Description: The multicomponent intervention will be consist of:~1. Training of the restaurant staff (waiters and cookers) about Mediterranean and Healthy Diet and food allergens,~2. Nutritional and food allergen analysis of the menu of the restaurant~3. Improvement of the menu to follow the Mediterranian diet standards (AMED criteria), the nutritional quality of the menu and the adaptations of the menu for food allergies and food intolerances~4. Marketing campaign about healthy and food allergen adapted menus in the restaurants
Study NCT00745615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod tablets/capsules will be administered as per the dose and schedule specified in the respective arms.
Study NCT00745615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to laquinimod will be administered as per the dose and schedule specified in the respective arms.
Study NCT02869984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Study NCT02378025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Group
Description: A 10-week yoga course designed to treat pain.
Study NCT02378025 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Management Wellness Group
Description: A 10-week behavioral therapy course designed to treat pain.
Study NCT01247181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile phone text message
Description: Weekly message with motivational content
Study NCT01247181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care provided at clinic
Study NCT04291378 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton versus photon radiation therapy
Description: The intervention is proton radiation therapy versus photon radiation therapy
Study NCT04291378 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton versus photon radiation therapy
Description: The intervention is proton radiation therapy versus photon radiation therapy